Alexandria Venture Investments
Alexandria Venture Investments is the strategic venture capital platform of Alexandria Real Estate Equities, Inc., investing in disruptive early-stage life science and agrifoodtech companies. Since its inception in 1996, the platform has deployed over $1.2B (adjusted cost basis as of Dec 2022) into transformative new modalities, platforms, and innovative medicines.
55% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $72.1M (across 243 rounds with reported amounts).
Portfolio
232
Fund Size
$1.2B
Top Stage
Series A
Last 12 Mo
24
Team
Ambassador James P. Cain
Independent Director
Blake L. Stevens
Executive Vice President – Regional Market Director – Research Triangle
Bret E. Gossett
Executive Vice President – Co-Regional Market Director & Head of Leasing – San Diego
Claire Aldridge, PhD
Independent Director
Hart Cole
Co-President & Co-Regional Market Director – Seattle
Hunter L. Kass
Co-President & Regional Market Director – Greater Boston
Jesse Nelson
Executive Vice President – Regional Market Director – San Francisco Bay Area
Joshua J. Mitchell
Executive Vice President – Regional Market Director – New York
Lawrence J. Diamond
Co-Chief Operating Officer & Co-Regional Market Director – Maryland
Maria C. Freire, PhD
Independent Director
Michael A. Woronoff
Independent Director
Michael E. Boss
Executive Vice President – Co-Regional Market Director – San Diego
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| CCrystalys Therapeutics | Series B | $130M | Jul 2026 |
| CCrystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 Create Medicines | Series B | $122M | May 2026 |
| FFathom Therapeutics | Series A | $47M | Apr 2026 |
 Neomorph | Series B | $100M | Apr 2026 |
 Ten63 | Unknown | — | Feb 2026 |
| TTRexBio, Inc. | Series C | $50M | Jan 2026 |
 TwoStep Therapeutics | Series A | $21.1M | Jan 2026 |
 Precede Biosciences | Series B | $63.5M | Jan 2026 |
 Recludix Pharma | Unknown | — | Jan 2026 |
 Trex Bio | Unknown | $50M | Jan 2026 |
| SSidewinder Therapeutics | Series B | $137M | Jan 2026 |
| Create Medicines | Series B | $122M | Jan 2026 |
 Alloy Therapeutics | Series E | $40M | Jan 2026 |
 Sidewinder | Series B | $137M | Jan 2026 |
 Solve Therapeutics | Unknown | $120M | Jan 2026 |
 Vedana Therapeutics | Series A | $46M | Jan 2026 |
| Solve Therapeutics | Series D | $120M | Nov 2025 |
 Accipiter Biosciences | Seed | $12.7M | Nov 2025 |
 Tr1X | Unknown | $50M | Oct 2025 |
 NILO Therapeutics | Series A | $101M | Oct 2025 |
 Crystalys | Series A | $205M | Sep 2025 |
| CCrystalys Therapeutics Inc | Series A | $205M | Sep 2025 |
 Dualitas Therapeutics | Series A | $65M | Sep 2025 |
 Leal Therapeutics | Series A | $30M | Aug 2025 |
Top Co-Investors
Last updated: 9 September 2026